263 related articles for article (PubMed ID: 37365430)
1. Exploration of the diagnostic capacity of PSAMR combined with PI-RADS scoring for clinically significant prostate cancer and establishment and validation of the Nomogram prediction model.
Li D; Zhang L; Xu Y; Wu X; Hua S; Jiang Y; Huang Q; Gao Y
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11309-11317. PubMed ID: 37365430
[TBL] [Abstract][Full Text] [Related]
2. Development of a nomogram combining multiparametric magnetic resonance imaging and PSA-related parameters to enhance the detection of clinically significant cancer across different region.
Zhou Z; Liang Z; Zuo Y; Zhou Y; Yan W; Wu X; Ji Z; Li H; Hu M; Ma L
Prostate; 2022 Apr; 82(5):556-565. PubMed ID: 35098557
[TBL] [Abstract][Full Text] [Related]
3. An integrated nomogram combining deep learning, Prostate Imaging-Reporting and Data System (PI-RADS) scoring, and clinical variables for identification of clinically significant prostate cancer on biparametric MRI: a retrospective multicentre study.
Hiremath A; Shiradkar R; Fu P; Mahran A; Rastinehad AR; Tewari A; Tirumani SH; Purysko A; Ponsky L; Madabhushi A
Lancet Digit Health; 2021 Jul; 3(7):e445-e454. PubMed ID: 34167765
[TBL] [Abstract][Full Text] [Related]
4. The prediction value of PI-RADS v2 score in high-grade Prostate Cancer: a multicenter retrospective study.
Chen S; Yang Y; Peng T; Yu X; Deng H; Guo Z
Int J Med Sci; 2020; 17(10):1366-1374. PubMed ID: 32624693
[No Abstract] [Full Text] [Related]
5. The potential of a nomogram combined PI-RADS v2.1 and contrast-enhanced ultrasound (CEUS) to reduce unnecessary biopsies in prostate cancer diagnostics.
Liu Y; Wang S; Xiang LH; Xu G; Dong L; Sun Y; Ye B; Zhang Y; Xu H
Br J Radiol; 2022 Sep; 95(1138):20220209. PubMed ID: 35877385
[TBL] [Abstract][Full Text] [Related]
6. PSA density is complementary to prostate MP-MRI PI-RADS scoring system for risk stratification of clinically significant prostate cancer.
Frisbie JW; Van Besien AJ; Lee A; Xu L; Wang S; Choksi A; Afzal MA; Naslund MJ; Lane B; Wong J; Wnorowski A; Siddiqui MM
Prostate Cancer Prostatic Dis; 2023 Jun; 26(2):347-352. PubMed ID: 35523940
[TBL] [Abstract][Full Text] [Related]
7. Prediction of false-positive PI-RADS 5 lesions on prostate multiparametric MRI: development and internal validation of a clinical-radiological characteristics based nomogram.
Cheng Y; Fan B; Fu Y; Yin H; Lu J; Li D; Li X; Qiu X; Guo H
BMC Urol; 2024 Apr; 24(1):76. PubMed ID: 38566091
[TBL] [Abstract][Full Text] [Related]
8. Development and external validation of a novel nomogram to predict prostate cancer in biopsy-naïve patients with PSA <10 ng/ml and PI-RADS v2.1 = 3 lesions.
Hu C; Sun J; Xu Z; Zhang Z; Zhou Q; Xu J; Chen H; Wang C; Ouyang J
Cancer Med; 2023 Feb; 12(3):2560-2571. PubMed ID: 35920264
[TBL] [Abstract][Full Text] [Related]
9. How to make clinical decisions to avoid unnecessary prostate screening in biopsy-naïve men with PI-RADs v2 score ≤ 3?
Zhang Y; Zeng N; Zhang F; Huang Y; Tian Y
Int J Clin Oncol; 2020 Jan; 25(1):175-186. PubMed ID: 31473884
[TBL] [Abstract][Full Text] [Related]
10. [Preliminary applicability evaluation of Prostate Imaging Reporting and Data System version 2 diagnostic score in 3.0T multi-parameters magnetic resonance imaging combined with prostate specific antigen density for prostate cancer].
Zuo MZ; Zhao WL; Wei CG; Zhang CY; Wen R; Gu YF; Li MJ; Zhang YY; Wu JF; Li X; Shen JK
Zhonghua Yi Xue Za Zhi; 2017 Dec; 97(47):3693-3698. PubMed ID: 29325321
[No Abstract] [Full Text] [Related]
11. [Developing a Chinese PI-RADS v2-based nomogram for predicting clinically significant prostate cancer in patients with a prior negative biopsy].
Huang C; Song G; Wang H; Ji GJ; Chen YK; He Q; Zhou LQ
Zhonghua Yi Xue Za Zhi; 2018 Aug; 98(32):2559-2563. PubMed ID: 30220139
[No Abstract] [Full Text] [Related]
12. Predicting Benign Prostate Pathology on Magnetic Resonance Imaging/Ultrasound Fusion Biopsy in Men with a Prior Negative 12-core Systematic Biopsy: External Validation of a Prognostic Nomogram.
Bjurlin MA; Renson A; Rais-Bahrami S; Truong M; Rosenkrantz AB; Huang R; Taneja SS
Eur Urol Focus; 2019 Sep; 5(5):815-822. PubMed ID: 29802053
[TBL] [Abstract][Full Text] [Related]
13. A magnetic resonance imaging-based nomogram for predicting clinically significant prostate cancer at radical prostatectomy.
Castellani D; Cecchini S; Mazzucchelli R; Soraci L; Di Rosa M; Fabbietti P; Palagonia E; Puccio F; Carnevali F; Paci E; Montironi R; Galosi AB
Urol Oncol; 2022 Aug; 40(8):379.e1-379.e8. PubMed ID: 35662497
[TBL] [Abstract][Full Text] [Related]
14. Based on PI-RADS v2.1 combining PHI and ADC values to guide prostate biopsy in patients with PSA 4-20 ng/mL.
Huang H; Liu Z; Ma Y; Shao Y; Yang Z; Duan D; Zhao Y; Wen S; Tian J; Liu Y; Wang Z; Yue D; Wang Y
Prostate; 2024 Mar; 84(4):376-388. PubMed ID: 38116741
[TBL] [Abstract][Full Text] [Related]
15. Development and Validation of a Radiomics Nomogram for Predicting Clinically Significant Prostate Cancer in PI-RADS 3 Lesions.
Li T; Sun L; Li Q; Luo X; Luo M; Xie H; Wang P
Front Oncol; 2021; 11():825429. PubMed ID: 35155214
[TBL] [Abstract][Full Text] [Related]
16. Can Prostate Imaging Reporting and Data System Version 2 reduce unnecessary prostate biopsies in men with PSA levels of 4-10 ng/ml?
Xu N; Wu YP; Chen DN; Ke ZB; Cai H; Wei Y; Zheng QS; Huang JB; Li XD; Xue XY
J Cancer Res Clin Oncol; 2018 May; 144(5):987-995. PubMed ID: 29504080
[TBL] [Abstract][Full Text] [Related]
17. Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies.
Radtke JP; Wiesenfarth M; Kesch C; Freitag MT; Alt CD; Celik K; Distler F; Roth W; Wieczorek K; Stock C; Duensing S; Roethke MC; Teber D; Schlemmer HP; Hohenfellner M; Bonekamp D; Hadaschik BA
Eur Urol; 2017 Dec; 72(6):888-896. PubMed ID: 28400169
[TBL] [Abstract][Full Text] [Related]
18. Developing a nomogram based on multiparametric magnetic resonance imaging for forecasting high-grade prostate cancer to reduce unnecessary biopsies within the prostate-specific antigen gray zone.
Niu XK; Li J; Das SK; Xiong Y; Yang CB; Peng T
BMC Med Imaging; 2017 Feb; 17(1):11. PubMed ID: 28143433
[TBL] [Abstract][Full Text] [Related]
19. PI-RADS v2.1 and PSAD for the prediction of clinically significant prostate cancer among patients with PSA levels of 4-10 ng/ml.
Wen J; Liu W; Shen X; Hu W
Sci Rep; 2024 Mar; 14(1):6570. PubMed ID: 38503972
[TBL] [Abstract][Full Text] [Related]
20. Development and validation of nomogram to improve the specificity of multiparametric MRI for clinically significant prostate cancer.
Shiekh M; Houenstein H; Ramahi YO; Shabir U; Ghadersohi S; Zhu D; Zhu M; Jing Z; Attwood K; Kauffman E; Aboumohamed A; Guru K; Hussein AA
Int J Urol; 2023 Oct; 30(10):876-882. PubMed ID: 37329258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
